Evidence map›Paper›PMID 39910066›Full record

ArticleNature communications2025

Neurovascularization inhibiting dual responsive hydrogel for alleviating the progression of osteoarthritis.

Wenpin Qin, Zhangyu Ma, Guo Bai, Wen Qin, Ling Li, Dongxiao Hao, Yuzhu Wang, Jianfei Yan, Xiaoxiao Han, Wen Niu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wenpin Qin *Department of Stomatology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, 710000, Shaanxi, China.ORCID http://orcid.org/0000-0003-3669-8095
Zhangyu Ma *Department of Stomatology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, 710000, Shaanxi, China.
Guo Bai *Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Wen QinState Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, The Fourth Military Medical University, Xi'an, 710000, Shaanxi, China.
Ling LiState Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, The Fourth Military Medical University, Xi'an, 710000, Shaanxi, China.
Dongxiao HaoState Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, The Fourth Military Medical University, Xi'an, 710000, Shaanxi, China.
Yuzhu WangState Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, The Fourth Military Medical University, Xi'an, 710000, Shaanxi, China.
Jianfei YanState Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, The Fourth Military Medical University, Xi'an, 710000, Shaanxi, China.
Xiaoxiao HanDepartment of Stomatology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, 710000, Shaanxi, China.
Wen NiuState Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, The Fourth Military Medical University, Xi'an, 710000, Shaanxi, China. niuwen9302@fmmu.edu.cn.
Lina NiuState Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, The Fourth Military Medical University, Xi'an, 710000, Shaanxi, China. niulina831013@126.com.ORCID http://orcid.org/0000-0002-6653-0819
Kai JiaoDepartment of Stomatology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, 710000, Shaanxi, China. kjiao1@163.com.ORCID http://orcid.org/0000-0002-1901-8329

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treating osteoarthritis (OA) associated pain is a challenge with the potential to significantly improve patients lives. Here, we report on a hydrogel for extracellular RNA scavenging and releasing bevacizumab to block neurovascularization at the osteochondral interface, thereby mitigating OA pain and disease progression. The hydrogel is formed by cross-linking aldehyde-phenylboronic acid-modified sodium alginate/polyethyleneimine-grafted protocatechuic acid (OSAP/PPCA) and bevacizumab sustained-release nanoparticles (BGN@Be), termed OSPPB. The dynamic Schiff base bonds and boronic ester bonds allow for injectability, self-healing, and pH/reactive oxygen species dual responsiveness. The OSPPB hydrogel can significantly inhibit angiogenesis and neurogenesis in vitro. In an in vivo OA model, intraarticular injection of OSPPB accelerates the healing process of condyles and alleviates chronic pain by inhibiting neurovascularization at the osteochondral interface. The injectable hydrogel represents a promising technique to treat OA and OA associated pain.

Indexed as

HydrogelsOsteoarthritisAlginatesAnimalsDisease Models, AnimalDisease ProgressionHumansHydroxybenzoatesInjections, Intra-ArticularMaleMiceNanoparticlesAlginatesHydrogelsHydroxybenzoatesprotocatechuic acid

Identifiers

PMID39910066
PMCPMC11799281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.